Navigation Links
Report Highlights Successful Strategies for Bringing FDC Products to Market
Date:1/5/2011

CHAPEL HILL, N.C., Jan. 5, 2011 /PRNewswire/ -- The pharmaceutical industry's steep patent cliff and relatively lackluster pipeline is pushing strategy and development executives to uncover opportunities for sustainable growth in 2011. One opportunity lies in combination therapies with branded products to extend patent life. For pharma companies, fixed dose combination (FDC) products can extend a therapeutic advantage and become part of lifecycle management. For the patient, FDC products can address unmet medical needs and reduce pill burdens.

While FDC products can have clinical and commercial advantages, they also can be challenging to bring to market. A new Best Practices, LLC report found it takes between five and eight years and an average of $80 million to bring a FDC product to market. One of the keys to successfully commercializing a FDC therapy is to create a differentiated product with a therapeutic benefit, according to the research project.

Indeed, critical product-shaping strategies such as positioning and value were tactics that veteran FDC leaders identified as most valuable for a successful launch of a FDC product, according to "Fixed Dose Combination Products: Successful Strategies for Developing and Bringing FDC Products to Market." As one R&D veteran noted in the report, "Bring some value to the payers. If a payer looks at it and there's not really any kind of clinical differentiation, whether it's better efficacy, speed of onset, better response, or better remission, the payers tell us very, very clearly that they're not interested."

Some of the issues addressed in this research include:

  • Chief reason for pursuing FDC development
  • Measures used to evaluate success
  • Years from decision to develop through launch
  • Cost of FDC product development Approximate
  • Difficulty areas for bringing FDC product to market
  • Reasons for partnering with another company to develop FDC product
  • Time lapsed from initial contact to signed contractual agreement with partner
  • U.S. filing routes used
  • EU filing routes used
  • Months from filing to approval
  • Pre-launch marketing challenges
  • Strategies, tactics, practices to help accelerate or impede launch progress
  • Lessons learned from executives
  • Metrics for effectively communicating business value

The full 55-page report contains more than 150 benchmark metrics, providing executives with the tools, tactics and techniques to help organizations successfully develop and commercialize fixed dose combination products. Review a complimentary summary of the study at http://www3.best-in-class.com/rr1037.htm. The summary includes selected best practices drawn from extensive primary research with 51 representatives from 34 leading companies, including eight of the Top 20 pharma companies. 

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.  For more information about the company, go to www.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Michigan Pre-Seed Capital Fund Reports Investments Totaling $2.5 Million in 2010
2. Elektas MOSAIQ Oncology Information System Named Category Leader in 2010 Top 20 Best in KLAS Awards Report
3. Reportlinker Adds Cosmetic Surgery Products
4. Complaints and Concerns about Medicare Competitive Bidding for Home Medical Equipment Can Be Reported Via a Toll-Free Number and Website
5. Reportlinker Adds Regenerative Medicine Markets
6. Reportlinker Adds Womens Health Diagnostic Testing
7. Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry
8. Reportlinker Adds E7: The Outlook for Pharmaceuticals to 2012
9. Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia
10. Reportlinker Adds The Outlook for Pharmaceuticals in Western Europe
11. Reportlinker Adds Mammography World Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... DUBLIN , Dec 9, 2016 ... Optical Transceiver Market 2016-2020" report to their offering. ... The report forecasts the ... during the period 2016-2020. The report covers the ... market for 2016-2020. To calculate the market size, the report considers ...
(Date:12/9/2016)... Mitsubishi Tanabe Pharma Corporation (Head Office: ... Dr. Masayuki Mitsuka ) has presented data that ... intravenously in 10-14 day cycles for 48 weeks experienced ... Functional Rating Scale-Revised (ALSFRS-R). The data were presented at ... Dublin, Ireland . In ...
(Date:12/9/2016)... -- Research and Markets has announced the addition of ... offering. ... global travel vaccines market to grow at a CAGR of 6.83% ... scenario and the growth prospects of the global travel vaccines market ... revenue generated from the sales of various vaccines administered to actively ...
Breaking Medicine Technology:
(Date:12/10/2016)... ... 2016 , ... Denver-based humanitarian aid organization, Saving Moses, is ... , The situation in Syria continues to worsen—deadly weapon explosions are increasing as ... disease. The situation is intensifying with winter coming and airstrikes increasing. , ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... Cellairis is ... and affordable repairs on iPhone , iPad and Samsung Galaxy devices ... Pearland Walmart in order to maximize convenience and accessibility for customers. While customers ...
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of fully-automated ... new solution for Emergency Departments (ED) has been added to their portfolio. Housed ... examination rooms, and with a simplified pallet of information available to the patient, ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
Breaking Medicine News(10 mins):